Eugene Sun, M.D.
Chief Executive Officer
Eugene Sun, M.D., joined Melinta Therapeutics in April 2013 as executive vice president, research and development. Prior to joining Melinta, Dr. Sun held multiple positions over a 17-year career at Abbott Laboratories where he most recently served as corporate vice president, global pharmaceutical clinical development. In this role, he was responsible for global clinical development, medical affairs, clinical operations and clinical pharmacology for the company’s pharmaceutical portfolio. Prior to 2005, he held various leadership positions in the Abbott R&D organization with responsibility for several therapeutic areas, including anti-infectives, as well as pharmacovigilance, quality assurance, medical affairs and health economics and outcomes research.
During his tenure at Abbott, Dr. Sun led the development and worldwide regulatory approval of the landmark HIV protease inhibitor Kaletra® and oversaw the development and approval of multiple indications for Humira®. He also had responsibility for the anti-infective development portfolio that included compounds in the quinolone, cephalosporin, macrolide and ketolide classes.
Dr. Sun served on the FDA Antiviral Drugs Advisory Committee from 2001 to 2007, and was a director of TAP Pharmaceuticals from 2004 to 2008.
He earned his M.D. from New York University School of Medicine. He completed his internship and residency in internal medicine, and his fellowship in infectious diseases, at the University of California, San Francisco, and was subsequently on the faculty at UCSF where he was an attending physician on the medical and infectious disease services. During his fellowship, Dr. Sun received a National Research Service Award and a Physician Scientist Award from the NIH. He earned his undergraduate degree from Harvard University.